1 Min Read
Oct 20 (Reuters) - NewLink Genetics Corp said it entered into a licensing agreement with Roche Holding AG to develop NewLink's cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1 billion in milestone payments.
NewLink's shares jumped nearly 26 percent before the bell on Monday.
Immunotherapies are a class of drugs designed to help the body's own immune system fend off disease. (Reporting by Natalie Grover in Bangalore; Editing by Saumyadeb Chakrabarty)